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Synergistic effects of longitudinal amyloid
and vascular changes on lobar microbleeds
ABSTRACT
Objective: To determine whether amyloid and hypertensive cerebral small vessel disease (hCSVD)
changes synergistically affect the progression of lobar microbleeds in patients with subcortical
vascular mild cognitive impairment (svMCI).
Methods: Among 72 patients with svMCI who underwent brain MRI and [11C] Pittsburgh com-
pound B (PiB)–PET, 52 (72.2%) completed the third year of follow-up. These patients were
evaluated by annual neuropsychological testing, brain MRI, and follow-up PiB-PET.
Results: Over 3 years, 31 of 52 patients (59.6%) had incident cerebral microbleeds (CMBs) in the
lobar and deep regions. Both baseline and longitudinal changes in lacune numbers were associ-
ated with increased numbers of lobar and deep microbleeds, while baseline and longitudinal
changes in PiB uptake ratio were associated only with the progression of lobar microbleeds, espe-
cially in the temporal, parietal, and occipital areas. Regional white matter hyperintensity severity
was also associated with regional lobar CMBs in the parietal and occipital regions. There were
interactive effects between baseline and longitudinal lacune number and PiB retention on lobar
microbleed progression. Increased lobar, but not deep, CMBs were associated with decreased
scores in the digit span backward task and Rey-Osterrieth Complex Figure Test.
Conclusions: Our findings suggest that amyloid-related pathology and hCSVD have synergistic
effects on the progression of lobar microbleeds, providing new clinical insight into the interaction
between amyloid burden and hCSVD on CMB progression and cognitive decline with implications
for developing effective prevention strategies. Neurology® 2016;87:1575–1582
GLOSSARY
AD 5 Alzheimer disease; ADL 5 activities of daily living; CAA 5 cerebral amyloid angiopathy; CMB 5 cerebral microbleed;
FLAIR 5 fluid-attenuated inversion recovery; GRE 5 gradient echo; hCSVD 5 hypertensive cerebral small vessel disease;
PiB 5 Pittsburgh compound B; RCFT 5 Rey-Osterrieth Complex Figure Test; SNSB 5 Seoul Neuropsychological Screening
Battery; SUVR 5 standardized uptake value ratio; svMCI 5 subcortical vascular mild cognitive impairment; WMH 5 white
matter hyperintensity.
Alzheimer disease (AD) and hypertensive cerebral small vessel disease (hCSVD) are major causes
of cognitive impairment in the elderly.1,2 There is increasing evidence that AD pathologies and
hCSVD coexist and interact in individuals with cognitive impairment.3 Recent amyloid PET
studies suggested that approximately 30% of patients with extensive hCSVD also had amyloid
lesions of the brain, showing a relationship between amyloid and hCSVD and their clinical
relevance.4,5
Cerebral microbleeds (CMBs) have generated a great deal of interest, since they are thought
to result from 2 key age-related small vessel pathologies, cerebral amyloid angiopathy (CAA) and
hCSVD, which may have different underlying causes and mechanisms.6,7 The topography of
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CMBs is thought to reflect their underlying
etiology8; however, recent studies on this issue
showed inconsistent results.9 Our group previ-
ously showed that amyloid burden and hCSVD
are synergistically associated with lobar
CMBs.10 A major limitation of studies to date
is that the association between neuroimaging
markers and CMBs has only been investigated
in cross-sectional studies,10 which limits the
exploration of cause-effect relationships.
In the current study, we investigated the
longitudinal effects of changes in amyloid
burden and hCSVD on the progression of
lobar and deep CMBs in patients with subcor-
tical vascular mild cognitive impairment
(svMCI). We hypothesized that amyloid and
hCSVD changes synergistically affect lobar
CMBs changes, while deep CMB changes
are only associated with hCSVD changes.
We also hypothesized that changes in CMBs
affect cognitive decline.
METHODS Participants. We prospectively recruited 72 pa-
tients with svMCI from September 2008 to September 2011 at
Samsung Medical Center. Patients with svMCI were diagnosed
using the previously described Petersen’s Criteria11 with the fol-
lowing modifications5: (1) a subjective cognitive complaint by the
patient or his or her caregiver; (2) normal activities of daily living
(ADL) score determined clinically and by the instrumental ADL
scale; (3) objective cognitive decline below the 16th percentile on
the Seoul Neuropsychological Screening Battery (SNSB); (4) no
dementia; (5) presence of a subcortical vascular feature defined as
a focal neurologic symptom/sign such as corticobulbar sign, pyra-
midal sign, or parkinsonism; and (6) significant white matter
hyperintensity (WMH) on MRI. Significant WMH was defined
as a hyperintensity in the periventricular white matter longer than
10 mm or hyperintensity in the deep white matter lesion more
than 25 mm in maximum diameter on fluid-attenuated inversion
recovery (FLAIR) imaging. The clinical characteristics of the
patients are shown in table 1.
Patients were evaluated by neuropsychological testing, labora-
tory testing, and MRI as described in a previous study.5 Brain
MRI confirmed the absence of structural lesions, including terri-
torial cerebral infarction, brain tumor, hippocampal sclerosis, and
vascular malformation.
Standard protocol approvals, registrations, and patient
consents. Written informed consent was obtained from each
patient. The Institutional Review Board of the Samsung Medical
Center approved the study protocol.
Neuropsychological tests. All patients underwent neuropsy-
chological testing using the SNSB.12 This battery includes quan-
titative tests, including digit span (forward and backward), the
Korean version of the Boston Naming Test, the Rey-Osterrieth
Complex Figure Test (RCFT; copying, immediate, and
20-minute delayed recall, and recognition), the Seoul Verbal
Learning Test (3 learning-free recall trials of 12 words,
a 20-minute delayed recall trial for these 12 items, and
a recognition test), the phonemic and semantic Controlled Oral
Word Association Test, Stroop Test (word and color reading of
112 items during a 2-minute period), the Mini-Mental State
Examination, and the Clinical Dementia Rating Sum of Boxes.
[11C] Pittsburgh compound B (PiB)–PET imaging. All pa-
tients underwent [11C] PiB-PET scanning at Samsung Medical
Center or Asan Medical Center with identical settings using
a Discovery STe PET/CT scanner (GE Medical Systems,
Milwaukee, WI). The detailed radiochemistry profiles, scanning
Table 1 Baseline and follow-up demographics and imaging characteristics
Baseline, n 5 72 Follow-up, n 5 52
Baseline age, ya 74.0 6 6.9 75.9 6 7.1
% Femaleb 45/72 (62.5) 35/52 (67.3)
Vascular risk factorsb
Hypertension 54/72 (75) 40/52 (76.9)
Diabetes mellitus 18/72 (25) 13/52 (25)
Hyperlipidemia 25/72 (34.7) 17/52 (32.7)
APOE genotypeb
e2 Allele-positive 11/72 (15.3) 9/52 (17.3)
e4 Allele-positive 19/72 (26.4) 12/52 (23.1)
MMSEa 26.2 6 2.9 24.3 6 5.0
CDR-SOBa 1.3 6 0.8 2.3 6 2.2
Lacunesc 4 (0–28) 5 (0–31)
Global PiB uptake ratioa 1.47 6 0.38 1.52 6 0.45
PiB positivity (>1.5)b 20/72 (27.8) 18/54 (33.3)
CMBs, totalc 1.5 (0–77) 2 (0–93)
Lobar CMBs 1.0 (0–39) 1 (0–47)
Frontal 0 (0–6) 0 (0–12)
Parietal 0 (0–13) 0 (0–7)
Temporal 0 (0–14) 0 (0–17)
Occipital 0 (0–10) 0 (0–11)
Deep CMBs 0 (0–48) 0 (0–55)
WMH severityd
Global WMH (0–84) 31.5 6 7.3 34.4 6 7.6
Frontal WMHe (0–38) 17.3 6 4.7 18.8 6 4.4
Parietal WMHf (0–6) 3.8 6 1.3 3.7 6 1.3
Temporal WMHg (0–6) 2.9 6 1.5 3.1 6 1.5
Occipital WMHh (0–8) 3.4 6 1.9 3.5 6 1.7
Abbreviations: CDR-SOB 5 Clinical Dementia Rating Sum of Boxes; CMB 5 cerebral
microbleed; MMSE 5 Mini-Mental State Examination; PiB 5 Pittsburgh compound B;
WMH 5 white matter hyperintensity.
a Continuous variables expressed as mean 6 SD.
bCategorical variables expressed as prevalence (%).
cContinuous variables expressed as median (minimum-maximum) (variables are not normally
distributed).
dWMH was measured using the Scheltens WMH scale.
e Frontal WMH consisted of frontal cap WMH (0–2), lobar frontal WMH (0–6), and basal
ganglia hyperintensity (0–30).
f Parietal WMH was defined as lobar parietal WMH located in the deep and subcortical white
matter.
g Temporal WMH was defined as lobar temporal WMH located in the deep and subcortical
white matter.
hOccipital WMH consisted of occipital cap WMH (0–2) and lobar occipital WMH (0–6).
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protocols, and PiB data analysis are described in appendix e-1 at
Neurology.org and were based on a previous study.5 To measure
PiB retention, we used the cerebral cortical region-to-cerebellum
uptake ratio, which was identical to the standardized uptake value
ratio (SUVR).
MRI techniques. Standardized T1, T2, FLAIR, and T2* gradi-
ent echo (GRE)MRI was performed for all participants at Samsung
Medical Center using the same 3.0T MRI scanner (Philips 3.0T
Achieva). T2* GRE-MRI was obtained using the following
parameters: axial slice thickness of 5.0 mm, interslice thickness of
2 mm, repetition time of 669 ms, echo time of 16 ms, flip angle of
188, and matrix size of 560 3 560 pixels.
Analysis of CMBs on GRE-MRI. CMBs were defined as le-
sions #10 mm in diameter and were also defined using criteria
proposed by Greenberg et al.13 Two experienced neurologists
who were blinded to patient data such as clinical information,
lacunes, WMH, and amyloid burdens reviewed the number and
location of CMBs on 20 T2* GRE-MRI axial slices. The 2
neurologists had an agreement kappa value for the presence of
CMBs of 0.92, and a consensus was reached in any initially
discrepant cases.
CMBs were counted in 4 lobar regions and also in deep brain
regions. Lobar CMBs depicted on the cortical surface model from
each group were displayed simultaneously using ParaView soft-
ware (paraview.org/; Kitware, Clifton Park, NY) as described in
appendix e-2.
Lacune and WMH assessment on MRI. A lacune was defined
as a lesion $3 mm and #15 mm in diameter with low signal
intensity on T1 imaging, high signal intensity on T2-weighted
imaging, and with a perilesional halo on FLAIR imaging. Two
experienced neurologists who were blinded to patient clinical data
reviewed the number and location of the lacunes on 80 axial FLAIR
slices. The kappa value between the 2 neurologists for the presence of
lacunes was 0.78, and a consensus was reached in any initially
discrepant cases.
The extent of WMH on FLAIR was also rated using the semi-
quantitative scale proposed by Scheltens and colleagues.14
Follow-up evaluations with neuropsychological testing,
MRI, and PiB-PET. Patients were evaluated annually with a clin-
ical interview, neuropsychological testing, and brainMRI for 3 years.
Of the 72 svMCI patients, 65 completed the first year of follow-up,
51 completed the second year, and 52 (72.2%) completed the third
year (figure e-1). The dropout rate was 27.8%. Among 72 patients
with svMCI, 13 patients developed dementia during the follow-up
period. Two patients experienced incident ICH during the 3-year
follow-up period.
A total of 50 (69.4%) patients underwent second PiB-PET at
a mean interval of 32.3 months (figure e-1). Those who dropped
out were older at baseline than those who completed follow-up
(p 5 0.024) and tended to have higher PiB retention at baseline
(p 5 0.076) (table e-1).
Statistical analysis. To evaluate whether the baseline PiB reten-
tion ratio and the number of lacunes affect the progression of mi-
crobleeds globally or regionally, a generalized estimating equation
with a negative binomial distribution was used for analysis after con-
trolling for age, sex, and the baseline PiB retention ratio or number
of lacunes. The interaction between baseline lacune number and
PiB retention ratio on the progression of microbleeds was explored,
including with the use of an interaction term (PiB retention ratio3
number of lacunes) in the above model.
To evaluate whether the PiB retention ratio or the number of
lacunes affects the progression of CMBs, a generalized estimating
equation with a negative binomial distribution was used for
analysis after controlling for age, sex, and longitudinal measures
of the PiB retention ratio or longitudinal measures of lacunes.
To evaluate the effects of WMH severity changes on CMB pro-
gression, WMH severity changes were included in the above
model instead of longitudinal measures of lacunes. In order to
evaluate the interactive effects of longitudinal measures of the
PiB retention ratio and number of lacunes on the progression
of microbleeds, an interaction term (longitudinal measures of
the PiB retention ratio 3 the number of lacunes) was included
in the above model.
To evaluate the relationship between CMB progression and
cognitive decline, a generalized estimating equation with a linear
model was used with neuropsychological scores as the dependent
variables and CMBs as the independent variables after controlling
for age, sex, education, and longitudinal measures of imaging
markers (amyloid burden and lacunes). Correction for multiple
comparisons was done using the false discovery rate method.
SAS software (SAS University Edition; SAS Institute, Cary,
NC) was used for all analyses.
RESULTS Longitudinal measures of lacunes, PiB retention,
and CMBs. In total, 43 of 72 (59.7%) patients had CMBs
at baseline. Over 3 years, 31 of 52 patients (59.6%) had
incident CMBs, increasing by 68 and 50 in the lobar and
deep regions, respectively. Three (5.8%) of 52 svMCI
patients had CMB counts decreasing by 10 and 9 in
the lobar and deep regions, respectively. The number
of lacunes increased from 6.8 6 7.4 to 7.9 6 8.2
and PiB SUVR increased from 1.47 6 0.38 to
1.52 6 0.45 in 52 patients monitored over 32.3
months (table 1). Figure 1 illustrates the distribution
and number of baseline and incident lobar CMBs in
the patient cohort.
Relationship of baseline and longitudinal measures of
lacunes and PiB retention with longitudinal measures of
lobar and deep CMBs. Higher lacune number at base-
line and longitudinal changes in lacune number were
associated with longitudinal increases in lobar CMB
numbers globally and regionally, as well as longitudi-
nal increases in deep CMB numbers (table 2). Higher
baseline number or longitudinal increases in PiB
retention were also associated with longitudinal in-
creases in lobar CMB numbers, especially in the pari-
etal, temporal, and occipital regions (table 2). There
were interactive effects between baseline and longitu-
dinal lacune number and PiB retention on longitudi-
nal global, parietal, temporal, and occipital lobar
CMB numbers (table 2).
We also analyzed the relationship of CMBs with
lacunes or amyloid burden at baseline and follow-
up after controlling for age, sex, and lacune number
or PiB uptake (table e-2). Higher lacune number
was associated with presence or higher number of
lobar and deep CMBs at both baseline and follow-
up. Neither the presence nor load of lobar/deep
CMBs was associated with baseline or follow-up
PiB uptake.
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Increased overall WMH severity tended to be
associated with increased deep CMBs (p 5 0.059)
and lobar CMBs in the parietal (p 5 0.06) and tem-
poral (p 5 0.053) regions (table 3). Regional WMH
severity was associated with regional lobar CMBs in
the parietal (p 5 0.001) and occipital (p 5 0.001)
regions (table 3).
In patients with aMCI without significant WMH,
higher lacune number at baseline and longitudinal
changes in lacune number were associated with longi-
tudinal increases in lobar CMB numbers (table e-3).
Higher lacune number at baseline was also associated
with longitudinal increases in deep CMB numbers
(table e-3). PiB retention was not associated with
lobar/deep CMBs (table e-3).
Relationship between longitudinal measures of CMBs
and neuropsychological results. Increased lobar CMBs
were associated with decreased scores on the digit
span backward and RCFT copy tests (table 4). There
were no significant relationships between longitudi-
nal measures of deep CMBs and decline in neuro-
psychological scores (table 4).
DISCUSSION Using 3 years of longitudinal amyloid
burden and hCSVD data, we investigated the
potential pathogenesis of lobar and deep CMB pro-
gression. Our major findings are as follows. First,
both baseline hCSVD and the progression of
hCSVD, as measured by lacune number, contrib-
uted to the progression of lobar and deep CMBs.
Second, both baseline amyloid deposition and its
progression, as measured by PiB retention, contrib-
uted to the progression of lobar, but not deep,
CMBs. Third, baseline and progression of hCSVD
and amyloid retention synergistically affected the
progression of lobar CMBs, especially in the
Table 2 Relationships between baseline and longitudinal imaging markers and longitudinal measures of lobar and deep cerebral microbleeds
(CMBs)
Longitudinal measures of lobar CMBs
Longitudinal measures
of deep CMBsLobar, overall Frontal Parietal Temporal Occipital
B (SE)a p B (SE) p B (SE) p B (SE) p B (SE) p B (SE) p
Baseline measures
Lacunes 0.09 (0.02) ,0.001 0.11 (0.02) ,0.001 0.11 (0.02) ,0.001 0.08 (0.02) 0.001 0.07 (0.03) 0.008 0.11 (0.02) ,0.001
PiB uptake ratio 1.57 (0.58) 0.007 20.12 (0.65) 0.850 1.97 (0.55) ,0.001 1.61 (0.66) 0.015 2.03 (0.63) 0.001 20.52 (0.54) 0.333
Interactionb 0.31 (0.06) ,0.001 NA NA 0.18 (0.06) 0.003 0.29 (0.07) ,0.001 0.43 (0.08) ,0.001 NA NA
Longitudinal
measures
Lacunes 0.09 (0.02) ,0.001 0.11 (0.02) ,0.001 0.10 (0.02) ,0.001 0.07 (0.02) 0.001 0.05 (0.02) 0.044 0.10 (0.02) ,0.001
PiB uptake ratio 1.20 (0.53) 0.024 20.58 (0.56) 0.300 1.64 (0.51) 0.001 1.34 (0.60) 0.025 1.41 (0.58) 0.014 20.55 (0.43) 0.206
Interactionb 0.24 (0.06) ,0.001 NA NA 0.13 (0.06) 0.038 0.24 (0.06) ,0.001 0.34 (0.07) ,0.001 NA NA
Abbreviations: NA 5 not applicable; PiB 5 Pittsburgh compound B.
Generalized estimating equation with a negative binomial distribution was conducted using CMBs in each region as the dependent variable and imaging
markers (lacunes, PiB retention) as the independent variables after controlling for age and sex.
a Values are presented as the regression coefficient (standard error).
b Including an interaction term for lacunes (continuous variable) and PiB retention ratio to covariates of the previous model.
Figure 1 The distribution of lobar cerebral microbleeds (CMBs)
Lobar CMBs from the gradient echo MRI axial scans of all patients were depicted on a single glass brain. Blue dots indicate
baseline lobar CMBs and red dots indicate newly developed CMBs.
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parietal, temporal, and occipital regions—areas
preferentially affected by CAA. Finally, increased
lobar CMBs contributed to a decline in attention
and visuospatial functions. Therefore, our findings
provide insight into the interaction between amy-
loid burden and hCSVD on the progression of
CMBs and cognitive decline.
Our longitudinal study builds upon the results of
a prior cross-sectional study, which revealed an inter-
action between amyloid burden and hCSVD on lobar
CMBs.10 Specifically, the current longitudinal study
showed that baseline amyloid burden and hCSVD
predicted the progression of lobar CMBs beyond
the degree predicted for either individual marker.
Table 3 Relationship between longitudinal measures of white matter hyperintensity (WMH) severity and cerebral microbleeds (CMBs)
Longitudinal changes
in WMH severity
Longitudinal changes in lobar CMBs
Longitudinal changes
in deep CMBsLobar, overall Frontal Parietal Temporal Occipital
B (SE) p B (SE) p B (SE) p B (SE) p B (SE) p B (SE) p
Overall 0.04 (0.03) 0.139 0.02 (0.03) 0.48 0.06 (0.03) 0.06 0.06 (0.03) 0.053 0.02 (0.03) 0.612 0.06 (20.03) 0.059
Frontal 20.02 (0.05) 0.709
Parietal 1.26 (0.37) 0.001
Temporal 0.40 (0.18) 0.581
Occipital 0.35 (0.11) 0.001
Generalized estimating equation with a negative binomial distribution was used with CMBs as the dependent variable and WMH score as the independent
variable after controlling for age, sex, and Pittsburgh compound B uptake ratio. Values are presented as the regression coefficients (standard error).
Table 4 Relationship between cerebral microbleeds (CMBs) and neuropsychological results
Longitudinal
neuropsychological results
Longitudinal measures of lobar CMBs Longitudinal measures of deep CMBs
B (SE)a p Corrected p B (SE)a p Corrected p
Digit span forward 20.013 (0.017) 0.4504 0.8366 20.015 (0.018) 0.4068 0.6509
Digit span backward 20.026 (0.008) 0.0013 0.0104 20.013 (0.008) 0.1197 0.383
K-BNT 20.017 (0.146) 0.9080 0.978 0.042 (0.333) 0.8989 0.8989
RCFT copyb 20.054 (0.016) 0.0007 0.0104 20.010 (0.020) 0.6028 0.8037
SVLT immediate recall 0.003 (0.047) 0.9529 0.978 20.119 (0.053) 0.0235 0.188
SVLT delayed recall 20.068 (0.037) 0.0665 0.266 20.069 (0.024) 0.0043 0.0688
SVLT recognition 20.045 (0.041) 0.2666 0.6094 20.028 (0.030) 0.3538 0.629
RCFT immediate recall 20.036 (0.060) 0.5546 0.8874 20.024 (0.076) 0.7531 0.8398
RCFT delayed recall 20.098 (0.071) 0.1692 0.4949 20.081 (0.076) 0.2864 0.5728
RCFT recognition 0.006 (0.027) 0.8246 0.978 20.011 (0.024) 0.6604 0.8128
COWAT animal 0.062 (0.047) 0.1856 0.4949 0.026 (0.037) 0.4875 0.7091
COWAT supermarket 0.012 (0.077) 0.8717 0.978 20.066 (0.049) 0.1775 0.4418
COWAT phonemic 0.005 (0.173) 0.9780 0.978 0.039 (0.145) 0.7873 0.8398
Stroop color 20.183 (0.452) 0.6862 0.978 20.346 (0.266) 0.1933 0.4418
K-MMSEb 20.030 (0.012) 0.0135 0.072 20.025 (0.015) 0.0851 0.3404
CDR-SOBc 0.007 (0.010) 0.4706 0.8366 0.015 (0.008) 0.0561 0.2992
Abbreviations: CDR-SOB 5 Clinical Dementia Rating Sum of Boxes; COWAT 5 Controlled Oral Word Association Test;
K-BNT 5 Korean version of Boston Naming Test; K-MMSE 5 Korean version of Mini-Mental State Examination; RCFT 5
Rey-Osterrieth Complex Figure test; SVLT 5 Seoul Verbal Learning Test.
Generalized estimating equation with linear modeling was conducted with neuropsychological test scores as the
dependent variables and CMBs as the independent variable after controlling for age, sex, education, and longitudinal
measures of imaging markers (Pittsburgh compound B uptake ratio and lacunes). Correction for multiple comparisons was
done using the false discovery rate method.
aValues are presented as the regression coefficient (standard error).
bData were transformed using a Box-Cox transformation prior to their inclusion in statistical analyses.
cData were transformed using a logarithmic transformation prior to their inclusion in statistical analyses.
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Moreover, longitudinal amyloid burden and hCSVD
also synergistically affected the progression of lobar
CMBs. These findings strongly suggest that lobar
CMBs are caused by an arteriopathy related to both
hCSVD and cerebral amyloid burden, while the arte-
riopathy causing deep CMBs is not related to cerebral
amyloid burden. The mechanism by which hCSVD
and amyloid pathology interact in the development of
lobar CMBs requires further investigation. CAA
shows a general predilection for the posterior brain
region (similar to the distribution of progressive
CMBs in our study),15 so it is possible that hCSVD
aggravates the deposition of vascular amyloid, or vice
versa. One potential pathophysiologic link is the peri-
vascular drainage pathways, an increasingly recog-
nized route for the elimination of interstitial fluid
and solutes, including b-amyloid, from the brain.16
Perivascular drainage may be impaired by hCSVD (as
indicated by MRI-visible perivascular spaces), leading
to impaired amyloid clearance with vascular deposi-
tion and more severe CAA with lobar CMB progres-
sion. Alternatively, CAA (reflected in increased PiB
retention)17 is also associated with MRI-visible perivas-
cular spaces in the cerebral hemisphere white matter,18
and may lead to the development of white matter small
vessel injury, leukoaraiosis, and CMB progression.17
Alternatively, amyloid burden and hCSVD might
affect other common pathways, including endothelial
dysfunction or inflammation,19 which in turn could
lead to increased vulnerability to small vessel occlusion
or hemorrhage.
One implication of our results is in the selection
and risk stratification of patients undergoing antipla-
telet or antiamyloid therapy. CMBs are of particular
interest because they are an important amyloid-
related imaging abnormality during amyloid immu-
notherapy in patients with cognitive impairment,20
with potential relevance in the prediction of this
adverse clinical effect; understanding the mechanisms
underlying CMBs may thus be useful in the design
and interpretation of future AD treatment trials.
Whether hCSVD is related to the risk of such com-
plications warrants further study. CMBs have also
been implicated as a risk factor for intracerebral hem-
orrhage following anticoagulant or antiplatelet ther-
apy.21,22 Tightly controlling vascular risk factors
reduces the progression of hCSVD, which might pre-
vent new-onset CMBs and the rate of hemorrhagic
complications in patients with combined amyloid and
hCSVD.
Our findings that both baseline hCSVD and its
progression contribute to the progression of lobar
and deep CMBs confirm a prior cross-sectional study
from our group.10 The hypothesis that deep CMBs
are associated with hCSVD has also been tested in
several longitudinal studies, which consistently
showed that a higher baseline burden or progression
of hCSVD predicts future deep CMBs.23,24 However,
previous results regarding incident lobar CMBs were
less consistent: 2 longitudinal studies showed that
baseline or incident lacunes were associated with
incident lobar CMBs,9,25 while a previous study did
not find a relationship between the progression of
hCSVD and incident strictly lobar CMBs.23 Our
findings support the notion that superficial perforating
arteries of pial origin are likely responsible for lobar
CMBs26 and may lose their autoregulatory function
in the presence of chronic hypertension and hCSVD,27
leading to excessive pressure, damage to smooth muscle
cells, and microbleeds.26 Consistent with 2 other lon-
gitudinal studies,9,25 our findings imply that lobar
CMBs not only reflect CAA.
We found that both baseline amyloid burden and
its progression affect the progression of lobar, but not
deep, CMBs. Our findings are consistent with a recent
CAA study showing that elevated PiB retention at
baseline precedes cerebral bleeding, including CMBs.28
Another longitudinal study showed that baseline PiB
status can be used to predict the incidence of strictly
lobar CMBs.25 PiB ligand binds to the fibrillary form
of amyloid in both parenchyma and vessel walls.29
Increased CAA severity is also reportedly associated
with increased neuritic plaques,30 although a previous
study found that only a quarter of patients with AD
display CAA extensive enough to cause lobar CMBs.31
Therefore, increased PiB SUVRmight reflect increased
CAA, which can lead to the progression of lobar
CMBs. It is also reasonable to infer that increased
amyloid vasculopathy contributes to the progression
of lobar CMBs over time, given that CAA has a pre-
dominantly posterior brain distribution.32 In fact, several
animal studies have provided evidence linking vascular
amyloid to disturbances in endothelial-dependent fac-
tors, causing disruption of cerebrovascular regulation
and extravascular leakage of blood components.33
We found that increased lobar CMBs, but not
deep CMBs, were associated with decreased scores
in attention and visuospatial functions. There has
been some controversy regarding the clinical influ-
ence of CMBs.24,34,35 Some previous studies suggested
that CMBs were clinically silent,36 while others re-
ported that CMBs were associated with cognitive
decline in elderly patients without dementia and
ischemic stroke patients.37,38 Our longitudinal study
demonstrated that longitudinal increases in CMBs
affect cognitive decline and evidenced regional spec-
ificity in the clinical significance of CMBs. There may
be several possible interpretations of our findings
regarding the relationship between lobar CMBs and
cognitive impairment in svMCI patients. The rela-
tionship between lobar CMBs and cognitive impair-
ment might be explained by CAA, considering that
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CAA is not only a key factor in CMBs, but it has also
been associated with cognitive impairment.39 Second,
CMBs may reflect the effect of co-occurring hCSVD
or AD, although the statistical significance remained
after controlling for PiB SUVR and lacunes. Finally,
the effects of CMBs on cognition may be due to
surrounding ischemic changes as well as direct focal
damage. However, results from this current study do
not fully address these hypotheses. Future studies
ought to investigate these complex relationships.
An important strength of this study is its 3-year pro-
spective cohort design using a standardized protocol.
Moreover, 70% of the participants underwent detailed
annual neuropsychological testing and structural MRI,
with a repeat PiB-PET scan after 3 years. However, there
were some limitations. First, although PiB-PET is the
most sensitive method available to reliably detect cerebral
amyloid in the vessel walls and parenchyma, this modal-
ity cannot differentiate these forms of amyloid deposi-
tion. Second, we measured longitudinal changes in
WMH severity using semiquantitative methods instead
of measurements of WMH volume because of technical
limitations. However, lacunes are a more specific marker
of hCSVD, sinceWMHmay be related to several differ-
ent pathologic processes.40 Third, our svMCI patients
were clinically diagnosed via clinical interview, neuro-
logic examination, and neuropsychological testing before
they underwent PiB-PET. However, the cognitive
symptoms of some svMCI patients with a significant
amyloid burden might be driven by AD pathology.
Finally, our study population included a large proportion
of patients with significant vascular burden, which
may limit the generalizability of our data to other
populations.
AUTHOR CONTRIBUTIONS
Yeo Jin Kim: study design, data analysis, drafting the manuscript. Hee Jin
Kim: interpretation of the data, manuscript revision. Jae-Hyun Park: analysis
and interpretation of the data. Seonwoo Kim: data analysis. Sook-Young
Woo: data analysis. Ki-Chang Kwak: data analysis. Jong Min Lee: data anal-
ysis. Na-Yeon Jung: interpretation of the data, manuscript revision. Jae Seung
Kim: conceptualization of the study. Yearn Seong Choe: conceptualization of
the study. Kyung-Han Lee: conceptualization of the study. Seung Hwan
Moon: conceptualization of the study. Jae-Hong Lee: conceptualization of
the study. Yun Joong Kim: interpretation of the data. David J. Werring:
interpretation of the data, manuscript revision. Duk L. Na: study design,
interpretation of the data. Sang Won Seo: study design, interpretation of
the data, manuscript revision.
STUDY FUNDING
This study was supported by the Korean Healthcare Technology R&D
Project (A102065), the KOSEF NRL program grant (MEST; 2011–
0028333), Samsung Medical Center (CRL-108011&CRS110-14-1),
and the Converging Research Center Program through the Ministry of
Education, Science, and Technology (2010K001054).
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received December 3, 2015. Accepted in final form June 28, 2016.
REFERENCES
1. Alzheimer’s Association. 2015 Alzheimer’s disease facts
and figures. Alzheimers Dementia 2015;11:332–384.
2. Fernando MS, Ince PG; MRC Cognitive Function Ageing
Neuropathology Study Group. Vascular pathologies and
cognition in a population-based cohort of elderly people.
J Neurol Sci 2004;226:13–17.
3. Shah NS, Vidal JS, Masaki K, et al. Midlife blood pres-
sure, plasma beta-amyloid, and the risk for Alzheimer dis-
ease: the Honolulu Asia Aging Study. Hypertension 2012;
59:780–786.
4. Lee JH, Kim SH, Kim GH, et al. Identification of pure
subcortical vascular dementia using 11C-Pittsburgh com-
pound B. Neurology 2011;77:18–25.
5. Lee MJ, Seo SW, Na DL, et al. Synergistic effects of
ischemia and beta-amyloid burden on cognitive decline
in patients with subcortical vascular mild cognitive impair-
ment. JAMA Psychiatry 2014;71:412–422.
6. Fazekas F, Kleinert R, Roob G, et al. Histopathologic
analysis of foci of signal loss on gradient-echo T2*-
weighted MR images in patients with spontaneous intra-
cerebral hemorrhage: evidence of microangiopathy-related
microbleeds. AJNR Am J Neuroradiol 1999;20:637–642.
7. Attems J. Sporadic cerebral amyloid angiopathy: pathol-
ogy, clinical implications, and possible pathomechanisms.
Acta Neuropathol 2005;110:345–359.
8. Vernooij MW, van der Lugt A, Ikram MA, et al. Preva-
lence and risk factors of cerebral microbleeds: the Rotter-
dam Scan Study. Neurology 2008;70:1208–1214.
9. Akoudad S, Ikram MA, Koudstaal PJ, et al. Cerebral mi-
crobleeds are associated with the progression of ischemic
vascular lesions. Cerebrovasc Dis 2014;37:382–388.
10. Park JH, Seo SW, Kim C, et al. Pathogenesis of cerebral
microbleeds: in vivo imaging of amyloid and subcortical
ischemic small vessel disease in 226 individuals with cog-
nitive impairment. Ann Neurol 2013;73:584–593.
11. Petersen RC, Smith GE, Waring SC, Ivnik RJ,
Tangalos EG, Kokmen E. Mild cognitive impairment: clin-
ical characterization and outcome. Arch Neurol 1999;56:
303–308.
12. Ahn HJ, Chin J, Park A, et al. Seoul Neuropsycholog-
ical Screening Battery-dementia version (SNSB-D):
a useful tool for assessing and monitoring cognitive
impairments in dementia patients. J Korean Med Sci
2010;25:1071–1076.
13. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cere-
bral microbleeds: a guide to detection and interpretation.
Lancet Neurol 2009;8:165–174.
14. Scheltens P, Erkinjunti T, Leys D, et al. White matter
changes on CT and MRI: an overview of visual rating scales:
European Task Force on age-related white matter changes.
Eur Neurol 1998;39:80–89.
15. Yamada M, Tsukagoshi H, Otomo E, Hayakawa M. Cere-
bral amyloid angiopathy in the aged. J Neurol 1987;234:
371–376.
16. Carare RO, Bernardes-Silva M, Newman TA, et al. Solutes,
but not cells, drain from the brain parenchyma along base-
ment membranes of capillaries and arteries: significance for
cerebral amyloid angiopathy and neuroimmunology. Neuro-
pathol Appl Neurobiol 2008;34:131–144.
17. Gurol ME, Viswanathan A, Gidicsin C, et al. Cerebral amy-
loid angiopathy burden associated with leukoaraiosis: a pos-
itron emission tomography/magnetic resonance imaging
study. Ann Neurol 2013;73:529–536.
Neurology 87 October 11, 2016 1581
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
18. Charidimou A, Jaunmuktane Z, Baron JC, et al. White
matter perivascular spaces: an MRI marker in pathology-
proven cerebral amyloid angiopathy? Neurology 2014;82:
57–62.
19. Whitehead SN, Cheng G, Hachinski VC, Cechetto DF.
Progressive increase in infarct size, neuroinflammation, and
cognitive deficits in the presence of high levels of amyloid.
Stroke 2007;38:3245–3250.
20. Boche D, Zotova E, Weller RO, et al. Consequence of Abeta
immunization on the vasculature of human Alzheimer’s dis-
ease brain. Brain 2008;131:3299–3310.
21. Thoonsen H, Richard E, Bentham P, et al. Aspirin in Alz-
heimer’s disease: increased risk of intracerebral hemorrhage:
cause for concern? Stroke 2010;41:2690–2692.
22. Orken DN, Uysal E, Timer E, Kuloglu-Pazarci N, Mumcu S,
Forta H. New cerebral microbleeds in ischemic stroke patients
on warfarin treatment: two-year follow-up. Clin Neurol Neu-
rosurg 2013;115:1682–1685.
23. Poels MM, Ikram MA, van der Lugt A, et al. Incidence of
cerebral microbleeds in the general population: the Rot-
terdam Scan Study. Stroke 2011;42:656–661.
24. Goos JD, Henneman WJ, Sluimer JD, et al. Incidence of
cerebral microbleeds: a longitudinal study in a memory clinic
population. Neurology 2010;74:1954–1960.
25. Yates PA, Desmond PM, Phal PM, et al. Incidence of cere-
bral microbleeds in preclinical Alzheimer disease. Neurology
2014;82:1266–1273.
26. Werring DJ. Cerebral Microbleeds: Pathophysiology to
Clinical Practice. Cambridge: Cambridge University Press;
2011.
27. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC.
Subcortical ischaemic vascular dementia. Lancet Neurol
2002;1:426–436.
28. Yates PA, Sirisriro R, Villemagne VL, et al. Cerebral mi-
crohemorrhage and brain beta-amyloid in aging and Alz-
heimer disease. Neurology 2011;77:48–54.
29. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-
mortem correlates of in vivo PiB-PET amyloid imaging in
a typical case of Alzheimer’s disease. Brain 2008;131:
1630–1645.
30. Boyle PA, Yu L, Nag S, et al. Cerebral amyloid angiopathy
and cognitive outcomes in community-based older per-
sons. Neurology 2015;85:1930–1936.
31. Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid
angiopathy in the brains of patients with Alzheimer’s dis-
ease: the CERAD experience, part XV. Neurology 1996;
46:1592–1596.
32. Dierksen GA, Skehan ME, Khan MA, et al. Spatial rela-
tion between microbleeds and amyloid deposits in amyloid
angiopathy. Ann Neurol 2010;68:545–548.
33. Niwa K, Carlson GA, Iadecola C. Exogenous A beta1-40
reproduces cerebrovascular alterations resulting from amy-
loid precursor protein overexpression in mice. J Cereb
Blood Flow Metab 2000;20:1659–1668.
34. Seo SW, Hwa Lee B, Kim EJ, et al. Clinical significance of
microbleeds in subcortical vascular dementia. Stroke 2007;
38:1949–1951.
35. Werring DJ, Frazer DW, Coward LJ, et al. Cognitive
dysfunction in patients with cerebral microbleeds on
T2*-weighted gradient-echo MRI. Brain 2004;127:
2265–2275.
36. Kato H, Izumiyama M, Izumiyama K, Takahashi A,
Itoyama Y. Silent cerebral microbleeds on T2*-weighted
MRI: correlation with stroke subtype, stroke recurrence,
and leukoaraiosis. Stroke 2002;33:1536–1540.
37. Yamashiro K, Tanaka R, Okuma Y, et al. Cerebral micro-
bleeds are associated with worse cognitive function in the
nondemented elderly with small vessel disease. Cerebro-
vasc Dis Extra 2014;4:212–220.
38. Gregoire SM, Scheffler G, Jager HR, et al. Strictly lobar
microbleeds are associated with executive impairment in
patients with ischemic stroke or transient ischemic attack.
Stroke 2013;44:1267–1272.
39. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ.
Cerebral amyloid angiopathy and cognitive function: the
HAAS autopsy study. Neurology 2002;58:1629–1634.
40. Gouw AA, Seewann A, van der Flier WM, et al. Heteroge-
neity of small vessel disease: a systematic review of MRI and
histopathology correlations. J Neurol Neurosurg Psychiatry
2011;82:126–135.
Share Your Artistic Expressions in Neurology ‘Visions’
AAN members are urged to submit medically or scientifically related artistic images, such as photo-
graphs, photomicrographs, and paintings, to the “Visions” section of Neurology®. These images are
creative in nature, rather than the medically instructive images published in the NeuroImages sec-
tion. The image or series of up to six images may be black and white or color and must fit into one
published journal page. Accompanying description should be 100 words or less; the title should be a
maximum of 96 characters including spaces and punctuation.
Learn more at www.aan.com/view/Visions, or upload a Visions submission at submit.neurology.org.
1582 Neurology 87 October 11, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/WNL.0000000000003220
2016;87;1575-1582 Published Online before print September 14, 2016Neurology 
Yeo Jin Kim, Hee Jin Kim, Jae-Hyun Park, et al. 
Synergistic effects of longitudinal amyloid and vascular changes on lobar microbleeds
This information is current as of September 14, 2016
Services
Updated Information &
 http://www.neurology.org/content/87/15/1575.full.html
including high resolution figures, can be found at:
Supplementary Material
 003220.DC1
http://www.neurology.org/content/suppl/2016/09/14/WNL.0000000000
Supplementary material can be found at: 
References
 http://www.neurology.org/content/87/15/1575.full.html##ref-list-1
This article cites 39 articles, 17 of which you can access for free at: 
  
Permissions & Licensing
 http://www.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
  
Reprints
 http://www.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
